厄洛替尼杂质 | 882420-22-6

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 厄洛替尼杂质
• 英文名称: 4-((6,7-Bis(2-methoxyethoxy)quinazolin-4-yl)amino)-2-ethynyl-phenol
• 英文别名: 4-[[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amino]-2-ethynylphenol
• CAS: 882420-22-6
• 化学式: C₂₂H₂₃N₃O₅
• 分子量: 409.4
• InChiKey: NEEHJGWAKAIBAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  95
• 氢给体数：
  2
• 氢受体数：
  8

ADMET

代谢

Erlotinib M16 已知的人体代谢物包括 4-[[6,7-双(2-甲氧基乙氧基)喹唑啉-4-基]氨基]-2-乙炔基苯基] 硫酸氢盐。

Erlotinib M16 has known human metabolites that include [4-[[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amino]-2-ethynylphenyl] hydrogen sulfate.

来源:NORMAN Suspect List Exchange

文献信息

• QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT
  申请人：Masse Craig E.

  公开号：US20090269354A1

  公开（公告）日：2009-10-29

  This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.

  本发明涉及新型喹唑啉衍生物及其药学上可接受的盐。本发明还提供了包含该化合物的组合物以及使用这种组合物治疗通过抑制细胞表面酪氨酸受体激酶有益地治疗疾病和状况的方法。
• [EN] QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT<br/>[FR] DÉRIVÉS DE QUINAZOLINE ET PROCÉDÉS DE TRAITEMENT
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2009121042A1

  公开（公告）日：2009-10-01

  This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.